OverviewSuggest Edit
QIAGEN N.V., through its subsidiaries, provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. The company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Technologies Sample Technologies: The company’s sample technologies provide access to the content of biological samples. These include solutions for the collection, stabilization, purification, handling and storage of any analyte (deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein) from any sample (blood, bone, and tissue).
| Type | Public | |
| Founded | 1984 | |
| HQ | Hilden, DE | Map |
| Website | qiagen.com | |
| Employee Ratings | More | |
| Overall Culture | A | More |
Recent NewsAll News
- Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens
- Tecan and Qiagen Collaborate to Automate Pre-Analytical Processing of Whole Blood Samples
- : Qiagen stock rises on announced COVID-19 test
- Qiagen to launch rapid coronavirus test it says could be used in airports and stadiums
Key People/Management at Qiagen
Thierry Bernard
Chief Executive Officer
Stéphane Bancel
Supervisory Director
Lawrence A. Rosen
Chairman of the Supervisory Board and Supervisory Director
Dominic O'Neil
Associate Director DNA Product Development
Stephany Foster
Senior Vice President, Head of Human Resources
Metin Colpan
Supervisory Director
Qiagen Office Locations
Qiagen has offices in Hilden, Bodman-Ludwigshafen, Germantown, Holmesglen and in 19 other locations
Hilden, DE (HQ)
1 Qiagen Str.
Bodman-Ludwigshafen, DE
Bodenseeallee 20
Antwerpen, BE
Quellinstraat 49
Toronto, CA
4400-181 Bay St
Shenzhen Shi, CN
4 Kewen Rd, Nanshan Qu
København, DK
Fruebjergvej 3
Qiagen Financials and Metrics
Qiagen Revenue
Market capitalization (25-Feb-2021) | 9.4b |
Closing stock price (25-Feb-2021) | 41.4 |
Qiagen's current market capitalization is €9.4 b.
Qiagen Cybersecurity Score
Qiagen Environment, Social & Governance (ESG) Ratings
Qiagen Online and Social Media Presence
15.32k Twitter followers
Qiagen has 15.32k Twitter Followers. The number of followers has increased 0.5% month over month and increased 1.3% quarter over quarter
Qiagen's Trends
Twitter Engagement Stats for @QIAGEN
3.9k
Tweets
841
Following
15.3k
Followers
34
Tweets last 30 days
2.2
Avg. likes per Tweet
76.5%
Tweets with engagement
Qiagen Company Culture
Overall Culture
A
82/100
CEO Rating
A+
90/100
Compensation
B+
78/100
Qiagen News and Updates
February 17, 2021
Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton...
February 04, 2021
Tecan and Qiagen Collaborate to Automate Pre-Analytical Processing of Whole Blood Samples
Tecan has launched the Fluent® Mix and Pierce Workstation* to provide end-to-end automation for whole blood pipetting in clinical environments.
read more
November 11, 2020
: Qiagen stock rises on announced COVID-19 test
Qiagen NV QGEN shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Qiagen shares rose 4% after hours, following a 0.9% rise in the regular session to close at $46.51. Called t…
September 08, 2020
Qiagen to launch rapid coronavirus test it says could be used in airports and stadiums
Qiagen CEO Thierry Bernard said the antigen tests are meant to supplement, not replace, the molecular, or PCR, tests, the most accurate tests on the market.
August 13, 2020
Press release from Davidson Kempner regarding Qiagen
LONDON, Aug. 13, 2020 /PRNewswire/ -- Davidson Kempner is pleased that the majority of investors have rejected the wholly inadequate offer made by Thermo Fisher Scientific. The low acceptance level of 47.02% is a clear signal that there is widespread confidence in the long-term prospects...
August 13, 2020
Press release from Davidson Kempner regarding Qiagen
LONDON, Aug. 13, 2020 /PRNewswire/ -- Davidson Kempner is pleased that the majority of investors have rejected the wholly inadequate offer made by Thermo Fisher Scientific. The low acceptance level of 47.02% is a clear signal that there is widespread confidence in the long-term prospects...
Qiagen Blogs
February 17, 2021
Using the Interactive Filter Cascade in QCI Interpret Translational
Whole-exome sequencing (WES) using next-generation sequencing (NGS) technology is a powerful tool for investigating variants linked to genetic disease. It...
The post Using the Interactive Filter Cascade in QCI Interpret Translational appeared first on Bioinformatics Software and Services | QIAGEN D…
February 17, 2021
Overcoming Challenges in Variant Filtering and Prioritization
Next-generation sequencing (NGS) techniques allow high-throughput detection of a vast amount of genetic variations in a cost-effective manner. However, there...
The post Overcoming Challenges in Variant Filtering and Prioritization appeared first on Bioinformatics Software and Services | QIAGEN Digi…
February 16, 2021
The key to target and biomarker discovery
Hint: The secret is in the biological context Today’s discovery scientists are challenged with identifying new biomarkers and therapeutic targets...
The post The key to target and biomarker discovery appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.
February 08, 2021
QIAGEN Digital Insights Publication Roundup (Spring 2021)
Read about how researchers across the world are using QIAGEN Digital Insights solutions to accelerate their work in a variety...
The post QIAGEN Digital Insights Publication Roundup (Spring 2021) appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.
January 15, 2021
HGMD Professional 2020.4 Release
The Winter 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of...
The post HGMD Professional 2020.4 Release appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.
January 15, 2021
Learn what’s new in the QIAGEN CLC Genomics version 21 (v21) release
Check out the new features of QIAGEN CLC Genomics Are you struggling to find a bioinformatics analysis tool that meets...
The post Learn what’s new in the QIAGEN CLC Genomics version 21 (v21) release appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.
Qiagen Frequently Asked Questions
When was Qiagen founded?
Qiagen was founded in 1984.
Who are Qiagen key executives?
Qiagen's key executives are Thierry Bernard, Stéphane Bancel and Lawrence A. Rosen.
How many employees does Qiagen have?
Qiagen has 5,300 employees.
Who are Qiagen competitors?
Competitors of Qiagen include Integrated DNA Technologies, VWR and Stemina Biomarker Discovery.
Where is Qiagen headquarters?
Qiagen headquarters is located at 1 Qiagen Str., Hilden.
Where are Qiagen offices?
Qiagen has offices in Hilden, Bodman-Ludwigshafen, Germantown, Holmesglen and in 19 other locations.
How many offices does Qiagen have?
Qiagen has 27 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies